Revlimid After Stem Cell Transplant Improves Survival in Myeloma – Curetoday.com
|
Revlimid After Stem Cell Transplant Improves Survival in Myeloma
Curetoday.com Patients with multiple myeloma saw a 26 percent decrease in risk of death when they took maintenance Revilmid (lenalidomide) after frontline treatment with high-dose Alkeran (melphalan) and autologous stem cell transplant (ASCT), when compared with … |
